Physician profile
Roberta Hellman
NPI 1992893143
$11,253.86
in general payments reported to CMS, 2019-2025
22 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,261 · 2020: $1,378 · 2021: $2,108 · 2022: $1,711 · 2023: $810 · 2024: $751 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,796.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $3,691.05 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $2,531.03 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $1,496.76 | 2019-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $791.05 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $667.62 | 2019-2023 | Austedo Xr |
| Alkermes, INC. | $581.40 | 2021-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $434.63 | 2019-2025 | Trintellix |
| Allergan, INC. | $341.59 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $151.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $94.35 | 2019-2021 | |
| Amarin Pharma, INC. | $94.04 | 2019 | |
| Janssen Biotech, INC. | $80.27 | 2019-2020 | |
| Indivior INC. | $46.29 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $42.97 | 2019-2020 | |
| Glaxosmithkline, LLC. | $41.34 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $38.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $30.57 | 2025 | Cobenfy |
| Phadia US INC. | $27.33 | 2019 | |
| Novo Nordisk INC | $21.08 | 2019 | |
| Amgen INC. | $19.05 | 2020 | |
| Endo Pharmaceuticals INC. | $17.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Hellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.